| # | Drug | Count |
|---|---|---|
| 0 | PEMBROLIZUMAB | 51 |
| 1 | NINTEDANIB | 28 |
| 2 | ENFORTUMAB VEDOTIN | 17 |
| 3 | PREDNISOLONE | 12 |
| 4 | PREDNISOLONE ORAL | 12 |
| 5 | PREDNISOLONE ORAL SOLUTION | 12 |
| 6 | FAM-TRASTUZUMAB DERUXTECAN-NXKI | 11 |
| 7 | METHOTREXATE SODIUM | 11 |
| 8 | NIVOLUMAB | 11 |
| 9 | SECUKINUMAB | 11 |
| # | Drug | Count | Frequency |
|---|---|---|---|
| 0 | LULICONAZOLE | 1 | 0.0057 |
| 1 | DIFLORASONE DIACETATE | 1 | 0.0052 |
| 2 | AMIVANTAMAB AND HYALURONIDASE-LPUJ (HUMAN RECOMBINANT) | 1 | 0.0033 |
| 3 | DIFLUPREDNATE OPHTHALMIC | 2 | 0.0023 |
| 4 | ENFORTUMAB VEDOTIN | 17 | 0.0022 |
| 5 | AZILSARTAN KAMEDOXOMIL | 5 | 0.0016 |
| 6 | AVELUMAB | 6 | 0.0015 |
| 7 | ZOLBETUXIMAB | 2 | 0.0013 |
| 8 | SENNOSIDES A AND B | 2 | 0.0012 |
| 9 | NALDEMEDINE | 2 | 0.0012 |
| # | Drug class | Count | Frequency |
|---|---|---|---|
| 0 | Claudin 18.2-directed Cytolytic Antibody [EPC] | 2 | 0.0013 |
| 1 | Interleukin-17 Receptor A Antagonist [EPC] | 1 | 0.0005 |
| 2 | Tyrosine Kinase 2 Inhibitor [EPC] | 1 | 0.0003 |
| 3 | Programmed Death Ligand-1 Blocker [EPC] | 5 | 0.0002 |
| 4 | Neonatal Fc Receptor Blocker [EPC] | 1 | 0.0002 |
| 5 | Vasopressin V2 Receptor Antagonist [EPC] | 3 | 0.0002 |
| 6 | Estrogen Receptor Antagonist [EPC] | 8 | 0.0002 |
| 7 | CTLA-4-directed Blocking Antibody [EPC] | 8 | 0.0002 |
| 8 | Phosphodiesterase 3 Inhibitor [EPC] | 1 | 0.0002 |
| 9 | Programmed Death Receptor-1 Blocking Antibody [EPC] | 11 | 0.0001 |